Adoptive cell therapy for metastatic melanoma patients: pre-clinical development at the Sheba Medical Center.
MJ Besser, AJ Treves, O Itzhaki, I Hardan… - The Israel Medical …, 2006 - europepmc.org
The Israel Medical Association journal: IMAJ, 2006•europepmc.org
Background Metastatic melanoma is an aggressive and highly malignant cancer. The 5 year
survival rate of patients with metastatic disease is less than 5% with a median survival of
only 6-10 months. Drugs like dacarbazin (DTIC) as a single agent or in combination with
other chemotherapy agents have a response rate of 15-30%, but the duration of response is
usually short with no impact on survival. Interleukin-2-based immunotherapy has shown
more promising results. The National Institutes of Health recently reported that …
survival rate of patients with metastatic disease is less than 5% with a median survival of
only 6-10 months. Drugs like dacarbazin (DTIC) as a single agent or in combination with
other chemotherapy agents have a response rate of 15-30%, but the duration of response is
usually short with no impact on survival. Interleukin-2-based immunotherapy has shown
more promising results. The National Institutes of Health recently reported that …
Background
Metastatic melanoma is an aggressive and highly malignant cancer. The 5 year survival rate of patients with metastatic disease is less than 5% with a median survival of only 6-10 months. Drugs like dacarbazin (DTIC) as a single agent or in combination with other chemotherapy agents have a response rate of 15-30%, but the duration of response is usually short with no impact on survival. Interleukin-2-based immunotherapy has shown more promising results. The National Institutes of Health recently reported that lymphodepleting chemotherapy, followed by an adoptive transfer of large numbers of anti-tumor specific tumor-infiltrating lymphocytes, resulted in an objective regression in 51% of patients.
Objectives
europepmc.org